Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRA Biomerica	$3.17 -9.7%	$3.29	$2.08 ▼ $10.16	$8.94M	0.26	2.02 million shs	696,973 shs
CLNN Clene	$3.62 +0.6%	$3.86	$2.28 ▼ $6.90	$29.76M	0.55	72,576 shs	13,854 shs
MDCX Medicus Pharma	$1.96 -1.0%	$2.74	$1.80 ▼ $8.94	$26.87M	N/A	332,164 shs	186,008 shs
MRSN Mersana Therapeutics	$7.16 -3.5%	$8.05	$5.21 ▼ $70.75	$37.03M	0.83	136,082 shs	79,994 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRA Biomerica	+13.96%	+12.86%	+17.59%	-3.57%	+43.85%
CLNN Clene	-1.37%	-1.91%	-2.70%	+40.08%	-27.42%
MDCX Medicus Pharma	-5.71%	-9.17%	-33.33%	-70.58%	+197,999,900.00%
MRSN Mersana Therapeutics	+8.96%	+12.25%	-8.98%	-12.73%	-75.87%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMRA Biomerica	1.1658 of 5 stars	0.0	5.0	0.0	3.2	0.8	0.0
CLNN Clene	3.2104 of 5 stars	3.6	4.0	0.0	2.1	2.5	0.6
MDCX Medicus Pharma	2.1365 of 5 stars	3.8	0.0	0.0	2.1	1.7	0.0
MRSN Mersana Therapeutics	4.0878 of 5 stars	3.5	4.0	4.1	1.1	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMRA Biomerica	0.00	N/A	N/A	N/A
CLNN Clene	3.17	Buy	$40.00	1,004.97% Upside
MDCX Medicus Pharma	3.50	Strong Buy	$23.50	1,098.98% Upside
MRSN Mersana Therapeutics	3.00	Buy	$56.60	690.50% Upside

Current Analyst Ratings Breakdown

Latest BMRA, CLNN, MRSN, and MDCX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00
8/14/2025	MRSN Mersana Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$250.00 ➝ $36.00
8/14/2025	MRSN Mersana Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$125.00 ➝ $30.00
8/13/2025	MRSN Mersana Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
8/13/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
7/18/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00
7/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
7/1/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/30/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00
6/23/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMRA Biomerica	$5.41M	1.49	N/A	N/A	$3.13 per share	1.01
CLNN Clene	$340K	88.05	N/A	N/A	($1.06) per share	-3.42
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	$0.24 per share	N/A
MRSN Mersana Therapeutics	$40.50M	0.88	N/A	N/A	($10.65) per share	-0.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMRA Biomerica	-$5.98M	-$2.32	N/A	∞	N/A	-85.42%	-85.90%	-61.06%	8/27/2025 (Estimated)
CLNN Clene	-$39.40M	-$4.04	N/A	N/A	N/A	-10,386.36%	N/A	-118.84%	8/20/2025 (Estimated)
MDCX Medicus Pharma	-$11.16M	-$1.34	N/A	N/A	N/A	N/A	-549.30%	-228.06%	N/A
MRSN Mersana Therapeutics	-$69.19M	-$14.75	N/A	N/A	N/A	-212.94%	-990.16%	-54.85%	N/A

Latest BMRA, CLNN, MRSN, and MDCX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CLNN Clene	-$0.49	-$0.78	-$0.29	-$0.78	$0.06 million	$0.03 million
8/13/2025	Q2 2025	MRSN Mersana Therapeutics	-$3.75	-$4.08	-$0.33	-$4.87	$6.06 million	$3.06 million
8/11/2025	Q2 2025	MDCX Medicus Pharma	-$0.39	-$0.43	-$0.04	-$0.43	N/A	N/A
5/15/2025	Q1 2025	MRSN Mersana Therapeutics	-$5.25	-$4.75	+$0.50	-$0.19	$6.05 million	$2.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMRA Biomerica	N/A	N/A	N/A	N/A	N/A
CLNN Clene	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A
MRSN Mersana Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMRA Biomerica	N/A	3.76	2.76
CLNN Clene	N/A	1.36	1.36
MDCX Medicus Pharma	N/A	1.29	1.53
MRSN Mersana Therapeutics	N/A	1.83	1.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMRA Biomerica	22.28%
CLNN Clene	23.28%
MDCX Medicus Pharma	N/A
MRSN Mersana Therapeutics	93.92%

Insider Ownership

Company	Insider Ownership
BMRA Biomerica	15.00%
CLNN Clene	35.30%
MDCX Medicus Pharma	11.20%
MRSN Mersana Therapeutics	13.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMRA Biomerica	60	2.55 million	2.16 million	Optionable
CLNN Clene	100	8.27 million	5.35 million	Optionable
MDCX Medicus Pharma	N/A	13.57 million	12.05 million	N/A
MRSN Mersana Therapeutics	150	4.99 million	4.34 million	Optionable

BMRA, CLNN, MRSN, and MDCX Headlines

Recent News About These Companies

Mersana Therapeutics price target adjusted to $36 at Truist after reverse split

August 14 at 2:12 PM | msn.com

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2025 Earnings Call Transcript

August 14 at 9:18 AM | insidermonkey.com

Mersana Therapeutics Reports Q2 2025 Financial Results

August 14 at 9:12 AM | msn.com

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2025 Earnings Call Transcript

August 14 at 9:12 AM | msn.com

Mersana Therapeutics reports Q2 EPS ($4.87), consensus ($4.25)

August 13 at 2:57 PM | msn.com

Mersana Therapeutics, Inc. (MRSN) Q2 2025 Earnings Call Transcript

August 13 at 12:06 PM | seekingalpha.com

Mersana Therapeutics, Inc.: Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results

August 13 at 9:34 AM | finanznachrichten.de

Mersana Misses Fiscal Q2 Revenue Target

August 13 at 9:34 AM | theglobeandmail.com

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results

August 13 at 9:34 AM | finance.yahoo.com

Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates

August 13 at 9:15 AM | zacks.com

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results

August 13 at 7:00 AM | globenewswire.com

Mersana Therapeutics Q2 2025 Earnings Preview

August 12 at 4:02 PM | msn.com

A Look at Mersana Therapeutics's Upcoming Earnings Report

August 12 at 4:02 PM | benzinga.com

Earnings To Watch: Mersana Therapeutics Inc (MRSN) Reports Q2 2025 Result

August 12 at 4:02 PM | finance.yahoo.com

Mersana Therapeutics (MRSN) to Release Quarterly Earnings on Wednesday

August 12 at 2:33 AM | americanbankingnews.com

Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025

August 6, 2025 | globenewswire.com

Mersana Therapeutics (NASDAQ:MRSN) Stock Price Down 5.3% - Here's What Happened

July 29, 2025 | marketbeat.com

Mersana Therapeutics trading halted, news pending

July 26, 2025 | msn.com

Mersana Therapeutics Presents Positive Phase 1 Data for Cancer Drug Emi-Le at ASCO 2025

July 25, 2025 | msn.com

Mersana Therapeutics Announces 1-for-25 Reverse Stock Split

July 24, 2025 | globenewswire.com

Mersana Therapeutics Settles Debt with Oxford Finance

July 3, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRA, CLNN, MRSN, and MDCX Company Descriptions

Biomerica NASDAQ:BMRA

$3.17 -0.34 (-9.69%)

Closing price 04:00 PM Eastern

Extended Trading

$3.02 -0.15 (-4.73%)

As of 07:59 PM Eastern

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Clene NASDAQ:CLNN

$3.62 +0.02 (+0.56%)

Closing price 03:59 PM Eastern

Extended Trading

$3.67 +0.05 (+1.38%)

As of 06:36 PM Eastern

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Medicus Pharma NASDAQ:MDCX

$1.96 -0.02 (-1.01%)

As of 04:00 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

Mersana Therapeutics NASDAQ:MRSN

$7.16 -0.26 (-3.50%)

Closing price 04:00 PM Eastern

Extended Trading

$7.24 +0.08 (+1.17%)

As of 07:50 PM Eastern

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time